Latest news on DiaSorin's response to COVID-19 outbreak
DiaSorin's response to COVID-19 continues through research projects that have been developed at the Saluggia and Gerenzano Centers in Italy.
In February and March, from the novel coronavirus outbreak, DiaSorin has promptly devised and developed a rapid and accurate molecular diagnostic test on our LIAISON MDX platform intended to detect all the currently known variants of the COVID-19. The test enables sample-to-answer results within less than 60 minutes compared to the 5-7 hours currently necessary to report patient results.
On April 17, DiaSorin announces that it has CE Marked the new LIAISON® SARS-CoV-2 S1/S2 IgG serological test and that it has received, on April 25, Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration.
The test responds to the need to identify the presence of antibodies in people who have been infected with SARS-CoV-2. With a throughput of 170 patient samples per hour, the LIAISON® XL platform can support an increase in testing capacity and the availability of diagnostic testing in order to mitigate the potential impact of this virus.
On May 12, DiaSorin announces that it has obtained approval for its LIAISON® SARS-CoV-2 S1/S2 IgG test from Health Canada, the Canadian government department responsible for federal health policy. Health Canada officials acknowledged that the DiaSorin test is the first serological test to receive authorization in the country.
On May 25, DiaSorin receives approval for the commercialization of the LIAISON® SARS-CoV-2 S1/S2 IgG test in Brazil from ANVISA, the Brazilian Health Regulatory Agency.
On June 30, DiaSorin announces that it has launched its new LIAISON® SARS-CoV-2 IgM test. The new test is now CE marked and available in the U.S. market, as part of the U.S. Food and Drug Administration’s process for ‘notification of validation and intent to submit an Emergency Use Authorization,’ outlined in the Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised).
On July 9, 2020 DiaSorin announces that its LIAISON® SARS-CoV-2 S1/S2 IgG test has been chosen by NHS England, the UK National Health Service, to assist with the completion of a National screening, tracking the impact and the circulation of the virus on the UK population.
- From Italy 800016268
- From other countries +39 0161 1895537
Carlo Rosa, CEO DiaSorin
June 30 - "Our IgM test is an additional diagnostic tool in the fight against COVID-19 that supports decisions to contain the pandemic. This test complements our recently launched molecular and IgG serology solutions and it confirms our full commitment in combating the spread of the infection. Let me thank our scientists who have been able, once again, to develop an innovative and reliable solution against COVID-19 with effectiveness and dedication. This product is part of a portfolio of innovative tools both in molecular and immunoassay technologies that DiaSorin is planning to launch by year end to support the medical community in the differential diagnosis between COVID-19 and other respiratory diseases."
DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients
The fully automated serology test for the detection of SARS-CoV-2 IgG Antibodies
Video clip for media
INTERVIEW WITH CARLO ROSA, DIASORIN GROUP CEO
Quarto Grado, Rete 4, 27 March 2020
INTERVIEW WITH CARLO ROSA, CEO OF DIASORIN GROUP
DiaSorin's response to COVID-19
CNBC Class, 19 March 2020
THE TRUMP ADMINISTRATION AWARDS DIASORIN TO DEVELOP RAPID COVID-19 TESTS FOR THE NEW CORONAVIRUS WITHIN ONE HOUR
A RAPID RESPONSE MOLECULAR DIAGNOSTIC TEST FOR THE CURRENT NOVEL CORONAVIRUS (COVID-19)
DiaSorin Group has officially announced it has completed the studies for the launch of a newly effective molecular diagnostic test for COVID-19, that has been developed by the DiaSorin Research Center in Gerenzano, near Milan.